EyePoint Pharmaceuticals, Inc. (EYPT)

NASDAQ: EYPT · IEX Real-Time Price · USD

16.75

+0.59 (3.65%)

At close: Apr 26, 2024, 4:00 PM

16.33

-0.42 (-2.51%)

After-hours: Apr 26, 2024, 7:46 PM EDT

EyePoint Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2002
Net Income	-70.8	-102.25	-58.42	-45.39	-56.79	-53.17	-18.49	-21.55	6.35	-13.36	Upgrade
Depreciation & Amortization	0.46	2.45	2.77	2.65	2.6	1.15	0.82	0.91	0.88	0.92	Upgrade
Share-Based Compensation	12.06	14.18	7.45	5.55	4.57	2.7	2.46	2.16	1.96	1.41	Upgrade
Other Operating Activities	60.15	20.63	-1.9	22.76	-7.08	27.41	-5.28	2.16	1.11	0.36	Upgrade
Operating Cash Flow	1.88	-65.01	-50.1	-14.44	-56.7	-21.91	-20.49	-16.32	10.3	-10.67	Upgrade
Capital Expenditures	-3.48	-2.15	-0.16	-0.36	-0.21	-0.11	-0.11	-0.11	-0.16	-0.17	Upgrade
Acquisitions	0	0	0	0	0	-16.78	0	0	0	0	Upgrade
Change in Investments	0.17	-15.12	-32.97	0	0	0	13.69	-4.35	-6.57	0.39	Upgrade
Other Investing Activities	-	-	-	-	-	-	-	-	-	-0.15	Upgrade
Investing Cash Flow	-3.32	-17.27	-33.12	-0.36	-0.21	-16.89	13.58	-4.46	-6.73	0.07	Upgrade
Share Issuance / Repurchase	229.55	0.4	217.2	50.21	23.04	42.02	8.5	16.99	0.24	19.04	Upgrade
Debt Issued / Paid	-41.86	-0.19	-0.15	-12.63	25.94	18.65	0	0	0	0	Upgrade
Other Financing Activities	-0.62	-0.89	-0.15	-0.09	-15.12	-	-	-	-	-	Upgrade
Financing Cash Flow	187.07	-0.69	216.9	37.49	33.86	60.67	8.5	16.99	0.24	19.04	Upgrade
Exchange Rate Effect	0	0	0	0	0	0	-0.01	-0.02	-0.01	-0	Upgrade
Net Cash Flow	185.63	-82.96	133.68	22.7	-23.05	21.88	1.59	-3.81	3.79	8.44	Upgrade
Free Cash Flow	-1.61	-67.16	-50.25	-14.8	-56.91	-22.02	-20.6	-16.43	10.14	-10.84	Upgrade
Free Cash Flow Margin	-3.49%	-162.19%	-136.04%	-42.97%	-279.46%	-743.50%	-273.30%	-1014.14%	38.16%	-312.15%	Upgrade
Free Cash Flow Per Share	-0.04	-1.80	-1.75	-1.15	-5.46	-4.76	-5.83	-5.20	3.45	-3.95	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).